HealthDay News — A tool has been developed that can improve standardization and transparency when describing cell therapies, according to a report published in the May 15 issue of the The Journal of Bone & Joint Surgery.
Iain R. Murray, Ph.D., from the University of Edinburgh in the United Kingdom, and colleagues established an international expert consensus on strategies to improve standardization and transparency when describing cell therapies. A working group convened an international consensus process involving clinicians and basic scientists; statements on communication of cell therapies were defined and a standardized tool was developed for describing cell therapies.
Using the Dephi process, 34 experts completed three rounds of a survey. The researchers found that after these rounds, 27 statements relating to existing nomenclature, solutions to improve communication, ideal framework characteristics, mandatory elements of a new framework, and future work to facilitate application reached consensus, with more than 80 percent agreement and less than 5 percent disagreement. When describing cell therapies, consensus was reached on the contents of a tool for improving standardization and transparency. The tool, termed “DOSES,” reports on five items: donor (source of cell), origin of tissue, separation from other cell types/preparation methods, exhibited cell characteristics associated with behavior, and site of delivery.
“In detailing key features of cells, the use of this tool may allow clinicians and patients to better understand the characteristics of current and future cell preparations,” the authors write.